J
J. Donald Easton
Researcher at University of California, San Francisco
Publications - 113
Citations - 22677
J. Donald Easton is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Stroke & Aspirin. The author has an hindex of 42, co-authored 104 publications receiving 20175 citations. Previous affiliations of J. Donald Easton include Brown University & Stanford University.
Papers
More filters
Journal ArticleDOI
Neuroprotection as Initial Therapy in Acute Stroke
Carlos Cantú,Jorge Villarreal,Jose Luis Soto,Fernando Barinagarrementeria,Benedikt Schoser,Veit U. Becker,Bernd Eckert,Hermann Zeumer,A. Thie,Lausanne J. Bogousslavsky,Mannheim M. Hennerici,M. Schmal,Carmine Marini,Antonio Carolei,M. Di Napoli,Fons Kessels,J. Lodder,Michael Eliasziw,J. David Spence,Henry J.M. Barnett,Dean M. Wingerchuk,Eelco F. M. Wijdicks,Jimmy R. Fulgham,Wouter I. Schievink,Jerry A. Katzmann,David G. Piepgras,G. Alistair Lammie,Joanna M. Wardlaw,Martin Dennis,J. Donald Easton,Adrià Arboix,L García-Eroles,J. Massons,Montserrat Oliveres,Keith W. Muir,Steven J. C. Hamilton,Martin W. Lunnon,Stephen F. Hobbiger,Kennedy R. Lees,José M. Ferro,Tony Pierre +40 more
TL;DR: The only firm guideline than can be proposed for patient selection is the need for early admission to enable neuroprotectant and/or thrombolytic treatment to be started as soon as possible within the therapeutic window, and more experimental data are needed.
Journal ArticleDOI
Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease
Cheryl Bushnell,Jeffrey Griffin,L. Kristin Newby,Larry B. Goldstein,Kenneth W. Mahaffey,Carmelo Graffagnino,Robert A. Harrington,Harvey D. White,R. John Simes,Robert M. Califf,Eric J. Topol,J. Donald Easton +11 more
TL;DR: In patients included in 3 trials of oral glycoprotein IIb/IIIa inhibitors, statin use is associated with a reduced risk of stroke but not severity or mortality, and women had more severe strokes than men.
Journal ArticleDOI
Mortality, kidney disease and cardiac procedures following acute coronary syndrome
Jula K. Inrig,Uptal D. Patel,Libbie P. Briley,Lilin She,Barbara S. Gillespie,J. Donald Easton,Eric J. Topol,Lynda A. Szczech +7 more
TL;DR: The risk of death greatly outweighed the risk of reduced eGFR or development of ESRD following ACS and the occurrence of cath +/- PCI was not associated with significant differences in long-term renal function.
Journal ArticleDOI
Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report
Gregory W. Albers,Richard A. Bernstein,Johannes Brachmann,John Camm,J. Donald Easton,Peter Fromm,Shinya Goto,Christopher B. Granger,Stefan H. Hohnloser,Elaine M. Hylek,Amir K. Jaffer,Derk W. Krieger,Rod S. Passman,Jesse M. Pines,Shelby D. Reed,Peter M. Rothwell,Peter R. Kowey +16 more
TL;DR: Stroke is a major public health issue worldwide and was the second‐leading cause of death behind heart disease globally, accounting for over 10% of total deaths worldwide in 2010.
Journal ArticleDOI
A global view of atherothrombosis:baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Deepak L. Bhatt,Keith A.A. Fox,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Marcus Flather,Steven M. Haffner,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon Hou Mak,J L Mas,G. Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Joan E. Booth,Eric J. Topol +23 more
TL;DR: The CHARISMA trial will further characterize atherothrombosis and provide insight into the role of dual antiplatelet therapy in improving outcomes in patients with multiple risk factors or established vascular disease.